Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
Thorac Cancer. 2021 Oct;12(20):2815-2818. doi: 10.1111/1759-7714.14112. Epub 2021 Aug 17.
Crizotinib showed significant antitumor effect in patients with advanced ROS1-rearranged non-small cell lung cancers (NSCLC). Most recently, many studies have explored the feasibility and efficacy of target therapy for perioperative application in NSCLC. Here, we describe a female patient who was diagnosed with stage IIIB lung adenocarcinoma exhibiting a CCDC6-ROS1 rearrangement by high-throughput sequencing. The tumor and lymph nodes showed durable response after the treatment of crizotinib. Given that a radiological downstaging was indicated, a right lower lobectomy and systemic lymphadenectomy were successfully performed. The pathological response was 60% and the tumor, nodes, and metastases (TNM) stage was ypT2bN0M0. The PD-L1 expression and activity of immunological cells were also investigated.
克唑替尼在晚期 ROS1 重排非小细胞肺癌（NSCLC）患者中显示出显著的抗肿瘤作用。最近，许多研究探索了 NSCLC 围手术期应用靶向治疗的可行性和疗效。在这里，我们描述了一名女性患者，该患者通过高通量测序被诊断为 IIIB 期肺腺癌，存在 CCDC6-ROS1 重排。肿瘤和淋巴结在接受克唑替尼治疗后显示出持久的缓解。鉴于影像学降期，成功进行了右下肺叶切除术和全身淋巴结清扫术。病理缓解率为 60%，肿瘤、淋巴结和转移（TNM）分期为 ypT2bN0M0。还研究了 PD-L1 表达和免疫细胞的活性。
